US FDA’s End-Of Year Approval ‘Rush’ And Other Criticisms: Fact Or Fiction?
Executive Summary
FDA has been criticized in recent months for approving drugs too quickly, based on insufficient evidence. The agency’s oncology chief Richard Pazdur fights back.